FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned

Authors

Max Gelman
Matthew Herder, Schulich School of Law, Dalhousie UniversityFollow

Document Type

News Article

Publication Date

2021

Keywords

Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Biopharmaceuticals, Food and Drug Administration

Abstract

The FDA’s controversial approval of Biogen’s Aduhelm drug for Alzheimer’s disease has been met with fierce resistance from all corners of the biopharma industry, but few seem to be as upset with the decision as ALS patients and advocacy groups.

Comments

Professor Matthew Herder was interviewed for this news article. He is quoted in paragraphs 19-20.

Recommended Citation

Max Gelman, "FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned", Endpoints News (18 June 2021), online: < endpts.com > [perma.cc/UZ7S-G936].